Marinus Pharmaceuticals, Inc. (MRNS) DCF Valuation

Marinus Pharmaceuticals, Inc. (MRNS) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Marinus Pharmaceuticals, Inc. (MRNS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Optimize your investment choices with the Marinus Pharmaceuticals, Inc. (MRNS) DCF Calculator! Utilize genuine Marinus financial data, adjust growth projections and expenses, and instantly observe how these changes affect the intrinsic value of Marinus Pharmaceuticals, Inc. (MRNS).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 1.7 15.3 25.5 31.0 45.5 66.9 98.3 144.4 212.1
Revenue Growth, % 0 0 793.19 66.03 21.63 46.92 46.92 46.92 46.92 46.92
EBITDA -54.4 -66.9 -95.5 -5.1 -125.5 -20.0 -29.4 -43.2 -63.5 -93.3
EBITDA, % 100 -3892.72 -622.53 -19.96 -404.97 -43.99 -43.99 -43.99 -43.99 -43.99
Depreciation .5 .6 .7 .7 .6 13.1 19.2 28.2 41.5 60.9
Depreciation, % 100 34.81 4.35 2.63 1.78 28.71 28.71 28.71 28.71 28.71
EBIT -54.9 -67.5 -96.2 -5.8 -126.0 -20.3 -29.8 -43.7 -64.3 -94.4
EBIT, % 100 -3927.53 -626.88 -22.59 -406.75 -44.52 -44.52 -44.52 -44.52 -44.52
Total Cash 91.7 138.5 122.9 240.6 150.3 45.5 66.9 98.3 144.4 212.1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 1.6 3.2 6.3 3.8
Account Receivables, % 100 95.81 20.76 24.92 12.26
Inventories .0 -6.3 -9.3 .1 2.4 -4.8 -7.0 -10.3 -15.2 -22.3
Inventories, % 100 -365.77 -60.66 0.30222 7.79 -10.51 -10.51 -10.51 -10.51 -10.51
Accounts Payable 2.8 2.2 3.1 4.5 4.0 22.8 33.6 49.3 72.4 106.4
Accounts Payable, % 100 128.7 20.37 17.51 12.92 50.16 50.16 50.16 50.16 50.16
Capital Expenditure -.4 .0 -2.9 -1.8 -.1 -2.4 -3.5 -5.1 -7.6 -11.1
Capital Expenditure, % 100 0 -18.83 -6.96 -0.38401 -5.23 -5.23 -5.23 -5.23 -5.23
Tax Rate, % 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08
EBITAT -54.6 -66.6 -99.0 -6.9 -124.7 -20.1 -29.6 -43.5 -63.9 -93.9
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -51.7 -62.0 -98.8 -19.3 -124.5 -2.7 -11.8 -17.3 -25.4 -37.3
WACC, % 14.47 14.4 14.56 14.56 14.42 14.48 14.48 14.48 14.48 14.48
PV UFCF
SUM PV UFCF -56.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -38
Terminal Value -305
Present Terminal Value -155
Enterprise Value -212
Net Debt -10
Equity Value -202
Diluted Shares Outstanding, MM 54
Equity Value Per Share -3.75

What You Will Get

  • Pre-Filled Financial Model: Marinus Pharmaceuticals' actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
  • Instant Calculations: Automatic updates ensure you see results as you make changes.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.

Key Features

  • Comprehensive Financial Data: Gain access to reliable pre-loaded historical financials and future forecasts for Marinus Pharmaceuticals, Inc. (MRNS).
  • Adjustable Forecast Parameters: Modify highlighted cells for crucial metrics like WACC, growth rates, and profit margins.
  • Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Dashboard: Utilize clear charts and summaries to easily interpret your valuation insights.
  • Suitable for All Skill Levels: An intuitive layout designed for investors, CFOs, and consultants, whether novice or expert.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Marinus Pharmaceuticals' data.
  • Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Marinus Pharmaceuticals' intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for Marinus Pharmaceuticals, Inc. (MRNS)?

  • Designed for Experts: A specialized tool tailored for analysts, CFOs, and industry consultants.
  • Accurate Data: Marinus Pharmaceuticals' historical and projected financials are preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth experience.

Who Should Use Marinus Pharmaceuticals, Inc. (MRNS)?

  • Investors: Gain insights into biopharmaceutical investments with our comprehensive analysis tools.
  • Healthcare Analysts: Streamline your research with detailed reports tailored for the biotech sector.
  • Consultants: Easily modify our resources for impactful presentations or client deliverables.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market strategies through real-case studies.
  • Educators and Students: Utilize our materials as a hands-on resource in pharmaceutical and healthcare education.

What the Template Contains

  • Historical Data: Includes Marinus Pharmaceuticals’ past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Marinus Pharmaceuticals’ intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Marinus Pharmaceuticals’ financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.